Mississippi Governor Tate Reeves has vetoed two significant bills aimed at expanding access to medical marijuana while signing a separate measure intended to support research into the psychedelic ibogaine for potential federal approval as a treatment option.
Despite receiving strong bipartisan support from legislators, the cannabis proposals faced rejection. One of the vetoed measures, the “Right to Try Medical Cannabis Act,” sought to create pathways for patients lacking specific qualifying conditions to access medical marijuana. Under the proposed bill (HB 1152) from Representative Lee Yancey (R), healthcare providers could have submitted petitions to the state’s Department of Health for patients suffering from chronic, terminal, or severely disabling illnesses. The state health officer would then have the authority to approve or deny these petitions.
In his veto message, Governor Reeves acknowledged the need for terminally ill patients to have access to various medications to alleviate suffering. However, he expressed concerns about amendments to the bill that would have removed residency requirements, which he argued would allow non-residents to access the state’s medical cannabis program, potentially compromising its integrity. Reeves emphasized the importance of maintaining a balance between medical and recreational marijuana usage.
Additionally, Reeves rejected another legislative effort aimed at broadening the range of products available under the medical marijuana program. This measure (HB 895), also sponsored by Yancey, aimed to eliminate restrictions on the potency of medical cannabis tinctures and oils, ease follow-up requirements for patients, and extend medical cannabis caregiver registrations from one year to two. The governor argued that these changes would undermine vital safeguards designed to prevent the diversion of medical cannabis for recreational use, asserting that the current law effectively limits marijuana access to those with legitimate medical needs.
In contrast, the governor approved HB 314, introduced by Representative Sam Creekmore IV (R), which establishes a consortium to conduct clinical trials on ibogaine. This new legislation, known as the “Ibogaine Drug Development Clinical Trial Act,” aims to facilitate research into ibogaine as a treatment for opioid addiction, co-occurring substance use disorders, and other neurological or mental health conditions. The bill includes provisions for the state to derive revenue from any resulting intellectual property or commercial rights.
The House further advanced legislation this session permitting terminally ill patients to access medical marijuana in hospital, nursing, and hospice settings, though this initiative has stalled in the Senate.
These developments underscore the complex landscape of cannabis legislation in Mississippi, highlighting the ongoing debate over medical marijuana access and the potential for psychedelics in treating serious health conditions.
